Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 3 Study of OCU 310 in Patients with Chronic Dry Eye Disease

Trial Profile

A Pivotal Phase 3 Study of OCU 310 in Patients with Chronic Dry Eye Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine/loteprednol-etabonate (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ocugen
  • Most Recent Events

    • 08 Apr 2019 According to an Ocugen media release, company is waiting for a full dataset from this trial and will provide an update once they complete full analysis.
    • 08 Apr 2019 Status changed from recruiting to completed, according to a Histogenics Corporation media release.
    • 01 Oct 2018 According to an Ocugen media release, topline data are expected in in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top